Alembic Ltd.
Snapshot View

70.55 +0.50 ▲0.7%

20 May 2022, 12:50:58 PM
Volume: 58,971

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.alembiclimited.com
Market Cap 1,829.57 Cr.
Enterprise Value(EV) 1,803.34 Cr. 2022-03
Financial Indicators
Earnings per share (EPS) 8.65 Trailing Twelve Months Ending 2022-03
Price-Earning Ratio (PE) 8.24 Trailing Twelve Months Ending 2022-03
Industry PE 28.47 Trailing Twelve Months Ending 2022-03
Book Value / Share 75.82 Trailing Twelve Months Ending 2022-03
Price to Book Value 0.93 Calculated using Price: 70.20
Dividend Yield 2.53 Period Ending 2021-03
No. of Shares Subscribed 25.68 Cr. 256,781,828 Shares
FaceValue 2
Company Profile

Alembic was incorporated in 1907 as Alembic Chemical Works Company, primarily engaged in production of tinctures and alcohol at Baroda. Later the company set up distillery plant for pharmaceutical purposes at Baroda. It started manufacturing of cough syrup, vitamins, tonics and sulphur drugs.

In 1952, the company set up its research and development activity. Currently the company has developed research activity in area of chemistry, microbiology, pharmaceutical technology and bio-equivalence.

The company’s manufacturing units are located in Baroda and Baddi. Company’s plant has received various certifications such as ISO-9002, ISO-14001 and ISO 27001 and also follows WHO-GMP guidelines.

The company has presence in 75 countries globally.

Business area

APIs- The Company is engaged in manufacturing of active pharmaceutical ingredients for anti-parkinsons, anti-depressants, cephalosporins, macrolides and others.

Bulk Pharmaceuticals- Under this the company manufactures bulk drugs that are phosgene based and intermediates.

Formulation- The company manufactures around 150 products under this segment in therapeutic areas such as anti-infective, cough and cold products to cardiovascular and oral anti-diabetics.

Herbal and Nutraceuticals- The company manufactures herbal and Nutraceuticals and has created brands like Isovon, Protinules, ALA-100, Diax and many more.

Alembic also provides contract research services in area of chemistry, bioequivalence and bioanalytical. It also manufactures products for animal care such as Antibiotics-injections, Analgesics, Antipyretics, antidiarrhoeals, Vitamins-Oral and injectable, Tonics and Nutritional feed supplements.

Outlook

The company has acquired API manufacturing unit of Nirayu that is located at Gujarat at a consideration of Rs 17.50 Crores.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+0.71%
1 Week
+3.29%
1 Month
-12.63%
3 Month
-23.15%
6 Month
-33.03%
1 Year
-46.59%
2 Year
+36.20%
5 Year
+58.18%
10 Year
+818.62%
9 years 2009-03 2010-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03
Return on Equity (%) 3.22 11.83 5.58 3.71 3.21 4.18 3.58 7.08 0.75
Return on Capital Employed (%) 7.79 10.54 3.82 3.82 3.12 4.44 3.91 7.12 0.94
Return on Assets (%) 1.08 3.82 2.88 3.25 2.94 3.88 3.39 6.80 0.71

Balance Sheet View Details

Particulars 8 years 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03* Rs. Cr.
Shh. Funds 528 803 911 1,086 1,209 1,418 2,297 2,497
Non Curr. Liab. 38 15 13 14 9 7 53 68
Curr. Liab. 82 58 68 59 49 46 59 68
Minority Int.
Equity & Liab. 648 876 992 1,159 1,266 1,471 2,409 2,632
Non Curr. Assets 458 706 801 972 1,167 1,308 2,307 2,489
Curr. Assets 189 169 191 187 99 163 102 143
Misc. Exp. not W/O
Total Assets 648 876 992 1,159 1,266 1,471 2,409 2,632

Profit Loss View Details

Particulars 8 years 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. TTM
Net Sales 144 128 147 125 124 74 74 78
Other Income 22 29 31 37 29 94 11 90
Total Income 166 156 178 162 153 167 84 167
Total Expenditure -135 -122 -140 -114 -106 -71 -63 -64
PBIDT 30 35 38 48 48 97 21 103
Interest -1 0 0 0 0 0 0 0
Depreciation -6 -6 -5 -4 -3 -3 -4 -5
Taxation 1 -1 1 -2 -4 0 -3 -12
Exceptional Items -3 -6
PAT 24 25 27 42 41 93 14 86
Minority Interest
Share Associate 82 210 118 121 172 236 329 136
Other Related Items
Consolidated Net Profit 107 235 145 163 213 329 343 222
Adjusted EPS 4 9 5 6 8 13 13 9

Cash Flow View Details

Particulars 7 years 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Cash Fr. Operatn. 22 10 52 24 22 7 -2
Cash Fr. Inv. 5 -5 -47 -22 72 57 -35
Cash Fr. Finan. -25 -5 -5 -3 -92 -6 -15
Net Change 2 0 0 -1 1 57 -52
Cash & Cash Eqvt 3 2 2 1 2 59 7

Shareholding Pattern View Details

9 Qtrs 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%)
Promoter 67.62 69.57 70.41 70.41 70.88 70.88 70.88 70.88 70.88
Public 32.38 30.43 29.59 29.59 29.12 29.12 29.12 29.12 29.12
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Thu, 19 May 2022
Loss of share certificate
Alembic Limited has informed the Exchange about Loss of share certificate
Thu, 19 May 2022
Related Party Transaction
Alembic Limited has informed the Exchange about related party transaction for the period ended March 2022
Wed, 18 May 2022
Related Party Transaction
Alembic Limited has informed the Exchange about related party transaction for the period ended March 2022

Technical Scans View Details

Thu, 19 May 2022
Close Within 52 Week Low Zone Close Within 52 Week Low Zone
High Decrease 1 Month High Decrease 1 Month
High Decrease 3 Months High Decrease 3 Months
High Decrease 6 Months High Decrease 6 Months
High Decrease 1 Year High Decrease 1 Year

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 212,197.18 912.40 +3.1%
Divi's Laboratories Ltd. 111,510.08 4,308.60 +2.6%
Cipla Ltd. 75,683.19 976.60 +4.1%
Dr. Reddy's Laboratories Ltd. 65,571.78 4,236.30 +7.8%
Apollo Hospitals Enterprise Ltd. 52,245.59 3,670.95 +1.1%
Gland Pharma Ltd. 51,277.11 3,051.95 -1.5%
Piramal Enterprises Ltd. 45,274.50 1,913.75 +1.0%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 32.93 912.40 +3.1%
Divi's Laboratories Ltd. Consolidated 2021-12 43.43 4,308.60 +2.6%
Cipla Ltd. Consolidated 2022-03 30.07 976.60 +4.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 30.04 4,236.30 +7.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-12 46.10 3,670.95 +1.1%
Gland Pharma Ltd. Consolidated 2021-12 43.23 3,051.95 -1.5%
Piramal Enterprises Ltd. Consolidated 2021-12 36.44 1,913.75 +1.0%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 4.11 912.40 +3.1%
Divi's Laboratories Ltd. Consolidated 2021-12 10.30 4,308.60 +2.6%
Cipla Ltd. Consolidated 2022-03 3.63 976.60 +4.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 3.41 4,236.30 +7.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-12 9.44 3,670.95 +1.1%
Gland Pharma Ltd. Consolidated 2021-12 7.47 3,051.95 -1.5%
Piramal Enterprises Ltd. Consolidated 2021-12 1.28 1,913.75 +1.0%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 0.08 912.40 +3.1%
Divi's Laboratories Ltd. Consolidated 2021-03 0.00 4,308.60 +2.6%
Cipla Ltd. Consolidated 2021-03 0.10 976.60 +4.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,236.30 +7.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 0.62 3,670.95 +1.1%
Gland Pharma Ltd. Consolidated 2021-03 0.00 3,051.95 -1.5%
Piramal Enterprises Ltd. Consolidated 2021-03 1.16 1,913.75 +1.0%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 912.40 +3.1%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 4,308.60 +2.6%
Cipla Ltd. Consolidated 2021-03 14.13 976.60 +4.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,236.30 +7.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,670.95 +1.1%
Gland Pharma Ltd. Consolidated 2021-03 20.97 3,051.95 -1.5%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 1,913.75 +1.0%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 912.40 +3.1%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 4,308.60 +2.6%
Cipla Ltd. Consolidated 2021-03 14.13 976.60 +4.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,236.30 +7.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,670.95 +1.1%
Gland Pharma Ltd. Consolidated 2021-03 20.97 3,051.95 -1.5%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 1,913.75 +1.0%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 33,498.14 912.40 +3.1%
Divi's Laboratories Ltd. Consolidated 2021-03 6,969.40 4,308.60 +2.6%
Cipla Ltd. Consolidated 2021-03 19,159.59 976.60 +4.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,236.30 +7.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 10,560.00 3,670.95 +1.1%
Gland Pharma Ltd. Consolidated 2021-03 3,462.88 3,051.95 -1.5%
Piramal Enterprises Ltd. Consolidated 2021-03 12,809.35 1,913.75 +1.0%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 2,284.68 912.40 +3.1%
Divi's Laboratories Ltd. Consolidated 2021-03 1,984.29 4,308.60 +2.6%
Cipla Ltd. Consolidated 2021-03 2,401.30 976.60 +4.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,236.30 +7.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 136.00 3,670.95 +1.1%
Gland Pharma Ltd. Consolidated 2021-03 996.96 3,051.95 -1.5%
Piramal Enterprises Ltd. Consolidated 2021-03 1,074.43 1,913.75 +1.0%